TABLE 1.
Patient characteristics from study 1 and 2
| Clinical data |
Total n = 79 (%) |
Study 1 N = 30 (%) |
Study 2 n = 49 (%) |
|
|---|---|---|---|---|
| Gender | Men | 64 (81) | 22 (73) | 42 (86) |
| Women | 15 (19) | 8 (27) | 7 (14) | |
| Median age, yrs. (range) | 68 (35‐82) | 68 (35‐82) | 68(48‐80) | |
| Stage | Locally advanced | 26 (33) | 13 (43) | 13 (27) |
| Metastatic | 53 (67) | 17 (57) | 36 (73) | |
| Treatmenta | Cisplatin + gemcitabine | 46 (59) | 22 (76) | 24 (49) |
| Carboplatin + gemcitabine | 9 (11) | 6 (21) | 3 (6) | |
| Vinflunine | 3 (4) | 1 (3) | 2 (4) | |
| Pembrolizumab | 20 (26) | 0 (0) | 20 (41) | |
a
One patient in study 1 never started treatment due to cerebral stroke before initiation of treatment.